Senior Benefit Assistance is a licensed Medicare agency. This guide was written by our licensed agents in October 2026 to explain what changed with Xarelto coverage for 2027 and what your options are. Talk to your doctor or pharmacist before changing any medication.
If you take Xarelto, your mailbox may have delivered an unpleasant surprise this fall: the blood thinner that was affordable under Medicare's negotiated pricing in 2026 is suddenly expensive for 2027. On community boards, beneficiaries are reporting cost shocks like $600 a year jumping to $9,500. One family ran the numbers for a father's full medication list and watched the yearly estimate climb from about $600 to about $9,500, with Xarelto the reason. Another member put the refill math bluntly: about $2,000 a refill for brand Xarelto, against about $50 more a refill for the alternative his family settled on. A third reports roughly $8,000 out of pocket ahead for the year.
"What a shame how this country treats older Americans."
That is the mood in thread after thread: people who did nothing wrong, facing a four-figure jump on a drug that keeps them safe from strokes and clots, and feeling forced to switch medications they tolerate well. One member wrote that switching to a different blood thinner caused nine months of significant hair loss: "I will not go back on Eliquis." This is a real crisis for real people. Here's what actually changed, and what you can actually do.
Why Xarelto lost its Medicare negotiated price for 2027
Medicare's Drug Price Negotiation Program set a negotiated price for Xarelto (rivaroxaban) for 2026, about $197 for a 30-day supply, roughly 62% below its list price. That was round one.
For 2027, Xarelto was removed from the negotiated-price list. The reason: a generic version appeared. Under the program's rules, when a generic or biosimilar alternative emerges, the brand drug comes off the negotiated list, regardless of dosage. The first generic rivaroxaban (2.5 mg tablets) was approved by the FDA in March 2025.
So the 2027 picture is split: the negotiated price is gone, and what you pay now depends on your drug plan's formulary: which tier it puts brand Xarelto on, and how it covers the generic.
What members are actually seeing for 2027
The first thing to know is that there is no single 2027 Xarelto story. Coverage is plan by plan, and the boards show the whole range:
- One member starting Medicare in November picked a Wellcare Part D plan, found Xarelto off its formulary entirely, and plans to switch drugs in January, expecting to save over $2,000 in 2027 by doing it.
- Another was told an Aetna Medicare Advantage plan covers Xarelto, with the warning that changing plans can mean changing a lot of your doctors to stay in network. A drug win that costs you your doctors is not a win.
- A claim circulating in the threads, that no Medicare drug plan includes Xarelto anymore, is wrong. Some plans dropped it, some kept it, and tiers differ. Your plan's 2027 formulary is the only answer that counts for you.
- Members also report the generic rivaroxaban costing very little on some plans and at some pharmacies. One Boise-area member described a 3-month supply of generic rivaroxaban filled at a major pharmacy chain for single-digit dollars on a low-premium Part D plan.
Timing matters here: Medicare.gov posted its formulary update on October 26, 2026. If you ran a plan comparison earlier in October, run it again. The numbers you saw may already be stale.
Generic rivaroxaban: why it's not a simple swap
This is the part that trips people up. Rivaroxaban comes in several doses for different jobs:
- 2.5 mg twice daily (with aspirin): for reducing cardiovascular risk in coronary or peripheral artery disease.
- 15 mg and 20 mg once daily: for atrial fibrillation and treating blood clots.
These are different indications with different dosing, and the way the drug is absorbed differs between dosages. Eight 2.5 mg tablets is not the same thing as one 20 mg tablet, a point a board member learned the hard way after that suggestion circulated online. Your dose exists for a reason tied to your condition. Never re-engineer your own dosing.
Buying Xarelto direct from the manufacturer: the J&J Direct workaround
The newest workaround members are passing around is buying brand Xarelto directly from the manufacturer through J&J Direct, a channel several members say they found through TrumpRx. The figure members report for the 20 mg dose is $2,364 out of pocket for a year. For someone staring at $2,000 a refill, that sounds like rescue. Before you count on it, understand the three catches members in the same threads named:
- None of it counts toward your Part D deductible or the $2,400 cap. The purchase bypasses your insurance entirely, so every dollar is on top of whatever your plan spends on your other drugs.
- The program can stop at any time. It is a manufacturer offering, not a Medicare benefit, and it carries no promise it will exist next year.
- The price members report is a member report. It is what posters in the threads say they were quoted; it is not a Medicare-published price, and your quote may differ.
One member's verdict on the arrangement: it "just seems like a racket" that the same drug costs so much less when bought around the insurance system. Whether or not you use the channel, price it against your full picture: what your plan charges for Xarelto if it is covered, what the generic costs on your plan, and what your other medications do to your deductible and cap math for the year.
The Canada route, and why it is tightening
Many members have bought generic rivaroxaban from Canadian pharmacies for years, and the reported prices explain why: members cite figures as low as $16 a month for the generic 20 mg dose from Canada, against roughly $150 a month for a U.S. workaround. That channel is now under pressure from a U.S. customs rule change that suspends the de minimis exemption for low-value parcels. The rule is not, as some posts claim, an outright ban on shipping prescription medications by mail, but members who rely on it expect delays and disruption, and that thread drew more new views in October 2026 than any other discussion on the boards. We cover the customs change in depth in our companion article, Canadian Pharmacies: The Customs Deadline Moved to January 20, 2027. Do not let a January refill depend on a channel that may not deliver it.
What about switching to Eliquis?
Eliquis (apixaban) is the other big blood thinner in the family, and both are Factor Xa inhibitors. But "same family" doesn't mean "same drug." They differ in how often you take them, food requirements, how kidneys affect the choice, and bleeding-risk profiles. Some people do fine switching; others, like the member quoted above, do not. In the threads, the relief is priced per refill: Eliquis at about $50 more a refill was "a lot better than $2,000 per refill," and several members have January switches planned. Others push back that a switch is "not easy for all," and they are right.
A switch is a prescriber decision, full stop. It deserves a conversation with the doctor who knows why you're on a blood thinner in the first place, and with your pharmacist, who can walk through what the change means day to day. Never switch anticoagulants on your own, and never stop one abruptly.
The $2,400 cap, and when it does not protect you
The most you'll pay out of pocket for covered Part D drugs in 2027 is $2,400 (up from $2,100 in 2026). That cap is real protection, with one condition members keep missing: it applies to covered drugs bought through your plan. If Xarelto is off your plan's formulary, buying it anyway, at a pharmacy counter or direct from the manufacturer, does not count toward your deductible or the cap. When you compare your options, compare them inside the cap math: a plan that covers your dose, even at a high tier, may cost you less over the year than a cheaper-premium plan that leaves you paying cash outside the cap.
A warning about AI answers
One more thing the boards surfaced in October 2026: someone pasted chatbot-generated "information" claiming Xarelto 20 mg is a special extended-release tablet that can't be split or substituted without bleeding danger. A community volunteer checked it against the National Institutes of Health and the drug's own labeling, which allows the tablet to be crushed, and told the thread to ignore the AI answer because "it was hallucinating." Treat AI-generated medical claims the way you'd treat a stranger's advice at the pharmacy counter: verify before you trust.
Your actual options before December 7
The Annual Enrollment Period runs October 15 through December 7, and drug coverage is one of the highest-value things to compare. If you are new to reading your plan's change notice, start with our guide to how to read your Annual Notice of Change, then work through these steps:
- Read your plan's 2027 formulary: not last year's. Check exactly where your Xarelto dose lands and what the generic costs on your plan.
- Recheck after the October 26 update: Medicare.gov posted its formulary update on October 26, 2026. Comparisons run earlier in October may be stale.
- Run your exact prescriptions through Medicare's Plan Finder at medicare.gov and compare total yearly cost, premium plus drug costs, not premium alone. The cheapest-looking plan is often not the cheapest plan for you.
- Ask your pharmacist about the generic: whether it's appropriate for your indication, and what it costs on your plan.
- Price the manufacturer-direct option honestly: if you consider J&J Direct, weigh the member-reported $2,364 a year against the fact that none of it counts toward your deductible or the $2,400 cap, and the program can end at any time.
- Talk to your doctor early: if a switch is on the table, do it with medical supervision and enough time to make sure the new drug agrees with you before January.
- Know the 2027 Part D cap: the most you'll pay out of pocket for covered Part D drugs in 2027 is $2,400 (up from $2,100). That's your worst case for covered drugs, and the benchmark every workaround should be measured against.
The bottom line: in 2026, Medicare's negotiated price held Xarelto to $197 for a 30-day supply. That price is gone for 2027, but you still have moves. The worst option is doing nothing and discovering the new price at the pharmacy counter in January.
Key terms
- Negotiated price (Maximum Fair Price): the price Medicare negotiates directly with a drug's manufacturer for a selected drug. While a drug stays selected, Part D plans must cover it at that price.
- Selected drug: a brand-name drug CMS picks for negotiation because it has no generic or biosimilar competition and ranks among Medicare's highest-spend drugs.
- Formulary: your plan's list of covered drugs, and the tier each drug sits on. It is the only document that settles what your plan covers.
- Tier: the cost level your plan assigns to a drug. Higher tiers usually mean you pay a percentage of the price instead of a flat copay.
- Deductible: the amount you pay for covered drugs each year before your plan starts sharing the cost.
- Out-of-pocket cap: the most you pay in a year for covered Part D drugs: $2,400 in 2027. Drugs bought outside your plan, including manufacturer-direct purchases, do not count toward it.
- Generic drug: an FDA-approved version of a brand drug with the same active ingredient. Rivaroxaban is the generic name of Xarelto.
- Factor Xa inhibitor: the drug class Xarelto and Eliquis belong to. They block factor Xa, a protein your body needs to form clots.
- Manufacturer-direct: buying a drug from the maker's own program, outside your insurance. The spending bypasses your deductible and the cap.
- De minimis: the customs rule that let low-value packages enter the country with minimal processing. Its suspension is what is tightening the Canadian mail route.
Primary sources
- CMS, Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026 (fact sheet, August 2024): Xarelto's negotiated price of $197 for a 30-day supply, 62% below its 2023 list price of $517.
- CMS, Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027 (fact sheet, November 25, 2025): negotiated prices for the 15 additional drugs selected for 2027; Xarelto, a 2026 drug, carries no negotiated price for 2027. Under the program's statute, 42 U.S.C. § 1320f-1(c), a selected drug leaves the program once a generic version is approved and is being marketed.
- U.S. Food and Drug Administration, FDA Roundup: March 4, 2025: approval of the first generic rivaroxaban 2.5 mg tablets, for coronary and peripheral artery disease.
- CMS, Announcement of Calendar Year (CY) 2027 Medicare Advantage Capitation Rates and Part C and Part D Payment Policies (April 6, 2026): the 2027 Part D out-of-pocket cap of $2,400.
- XARELTO (rivaroxaban) full prescribing information, DailyMed (National Library of Medicine): dosing by indication, and section 2.6, which states the tablets may be crushed.
- TrumpRx.gov: the federal site members describe using to reach manufacturer-direct pricing.
- Medicare.gov Plan Finder: plan-by-plan 2027 formulary and total-cost comparisons.
Questions members are asking about Xarelto and Medicare in 2027
Why is Xarelto so expensive in 2027?
Medicare's negotiated price for Xarelto applied to 2026 only. For 2027, Xarelto was removed from the negotiated-price list because a generic version appeared, and under the program's rules a brand drug leaves the list when a generic or biosimilar alternative emerges. What you pay now depends on your own drug plan's 2027 formulary: the tier your plan puts Xarelto on, and how it covers the generic.
Is there a generic for Xarelto?
Yes. Generic rivaroxaban reached the market starting with the 2.5 mg tablets, approved by the FDA in March 2025. The doses are not interchangeable: 2.5 mg twice daily is for reducing cardiovascular risk in coronary or peripheral artery disease, while 15 mg and 20 mg once daily are for atrial fibrillation and treating blood clots. Never combine smaller tablets to make up a larger dose, and ask your pharmacist whether the generic fits your indication.
Does the $2,400 Part D out-of-pocket cap apply to Xarelto?
Only when Xarelto is a covered drug on your plan. The 2027 cap of $2,400 (up from $2,100 in 2026) limits what you pay out of pocket for covered Part D drugs. If your plan does not cover Xarelto, or you buy it outside your plan, for example directly from the manufacturer, that spending does not count toward your deductible or the cap.
Should I switch from Xarelto to Eliquis?
That is a decision for you and your prescriber, not a swap to make on your own. Eliquis (apixaban) is in the same drug family, but the two differ in dosing, food requirements, how kidneys affect the choice, and bleeding-risk profiles. Some members switch without trouble; one member reported nine months of significant hair loss on Eliquis and refuses to go back. Never switch anticoagulants on your own, and never stop one abruptly.
What should I do before December 7?
Check your plan's 2027 formulary for your exact Xarelto dose, recheck it after Medicare.gov's October 26, 2026 formulary update, and run your exact prescriptions through Medicare's Plan Finder at medicare.gov, comparing total yearly cost rather than premium alone. Ask your pharmacist what the generic costs on your plan, and talk to your doctor early if a switch is on the table. The Annual Enrollment Period ends December 7.
Sources: CMS Medicare Drug Price Negotiation Program (negotiated-price fact sheets for 2026 and 2027); U.S. Food and Drug Administration (first generic rivaroxaban approval, March 4, 2025); CMS CY2027 Rate Announcement (2027 Part D out-of-pocket cap); XARELTO prescribing information, DailyMed. Full citations are in Primary sources below. Beneficiary experiences paraphrased from public community-board discussions, October 2026.